1.19
전일 마감가:
$1.18
열려 있는:
$1.21
하루 거래량:
93,731
Relative Volume:
0.34
시가총액:
$96.29M
수익:
-
순이익/손실:
$-21.65M
주가수익비율:
-3.5833
EPS:
-0.3321
순현금흐름:
$-15.84M
1주 성능:
+3.48%
1개월 성능:
-8.46%
6개월 성능:
-48.71%
1년 성능:
-23.23%
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
명칭
Cardiol Therapeutics Inc
전화
-
주소
-
CRDL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CRDL
Cardiol Therapeutics Inc
|
1.19 | 96.29M | 0 | -21.65M | -15.84M | -0.3321 |
![]()
ZTS
Zoetis Inc
|
163.16 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.16 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.39 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.24 | 18.62B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
131.60 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-28 | 개시 | Rodman & Renshaw | Buy |
2024-06-26 | 개시 | ROTH MKM | Buy |
2024-04-22 | 개시 | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Atria Investments Inc Takes Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Schedules Annual General Meeting for May 2025 - TipRanks
Financial Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Cortexyme (NASDAQ:CRTX) - Defense World
Cardiol Therapeutics to Present at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics to present at health care conference - Proactive Investors USA
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile
Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month LowWhat's Next? - MarketBeat
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Investing News Network
Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World
Promising Potential of Cardiol Therapeutics’ CRD-38 Justifies Buy Rating Amidst Market Need for HFpEF Treatment - TipRanks
Cardiol Therapeutics Inc. - MENAFN.COM
JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance
Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news
Cardiol Therapeutics reports heart failure treatment progress - Investing.com India
Cardiol Therapeutics Advances Heart Failure Treatment with New Research Publication - TipRanks
Revolutionary Heart Failure Treatment Shows Promise: Top Medical Journal Validates Multiple Therapeutic Benefits - StockTitan
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts (NASDAQ:CRDL) - Seeking Alpha
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis - Newsfile
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot - Newsfile
Biogen (NASDAQ:BIIB) vs. Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Contrast - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.7%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 7.7% – Time to Sell? - Defense World
Cardiol Therapeutics (OTCMKTS:CRTPF) Trading 5.3% Higher – Here’s Why - Armenian Reporter
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 5.3% – Time to Buy? - Defense World
Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors UK
Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile
Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Yahoo Finance
Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat
Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World
Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc (CRDL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):